MMP-28 (epilysin) is a recently cloned member of the MMP (matrix metalloproteinase) family. It is highly expressed in the skin by keratinocytes, the developing and regenerating nervous system and a number of other normal human tissues, as well as a number of carcinomas. The MMP28 promoter has previously been cloned and characterized identifying a conserved GT-box that binds Sp1/Sp3 (specificity proteins 1 and 3) proteins and is essential for the basal expression of the gene. The present study demonstrates that MMP28 expression is induced by HDAC (histone deacetylase) inhibitors and that this effect is mediated through the GT-box. Transient transfection assays have shown that the induction of MMP28 expression by the HDAC inhibitior TSA (trichostatin A) is mediated via Sp1 at the GT-box. Immunoprecipitation experiments have shown that the acetylation of Sp1 and Sp3 is increased by TSA treatment; however, no effect on DNA binding was observed. Histone acetyltransferases such as p300 and P/CAF [p300/CREB (cAMP-response-element-binding protein)-binding protein-associated factor] increased induction of the MMP28 promoter by Sp1. Knockdown of HDAC1 using siRNA (small interfering RNA) also induces the MMP28 promoter. Oligonucleotide pulldown identified STRAP (serine/threonine kinase receptor-associated protein) as a further protein recruited to the MMP28 promoter and acting functionally with Sp1.
INTRODUCTION
MMPs (matrix metalloproteinases) are a family of 23 structurally related enzymes in humans that are able to remodel and degrade the ECM (extracellular matrix). MMPs are also able to act on non-ECM components to mediate release and activation of soluble factors, such as growth factors and cytokines from the ECM [1] . A range of evidence strongly implicates MMPs in physiological (e.g. embryonic development and wound healing) and pathological (e.g. tumour growth and metastasis, cartilage destruction in arthritis and cardiovascular disease) events.
MMP-28, also known as epilysin, is a previously cloned member of the MMP family [2] . The primary sequence of MMP-28 has homology with the other members of the MMP family, containing a signal sequence, propeptide, zinc-binding catalytic domain and haemopexin-like C-terminal domain. Within the propeptide is a furin-activation sequence, with both mouse [3] and human [4] MMP-28 shown to be furin-activated. The exon-intron structure of the MMP28 gene is unusual among MMPs, and there is evidence that it undergoes alternative splicing [3] . Northern blot analysis suggests that the MMP28 gene is strongly expressed in testis, and also in lung, heart, colon, intestine and brain [3, 5] . It is also expressed in the developing and regenerating nervous system prior to myelination, as well as in several carcinomas [6, 7] . We have previously reported expression of MMP28 in human cartilage and synovium with significantly increased expression in osteoarthritis [8, 9] . The only substrate reported for MMP-28 is casein, a non-specific substrate for many proteinases [2] .
Since MMP-28 is expressed strongly in keratinocytes, its expression in wound healing has been examined. The MMP-28 protein is expressed in the basal and suprabasal epidermis in intact skin, while, in injured skin, expression is seen in basal keratinocytes both at and some distance from the wound edge; this is distinct from other MMPs [2] . Injury to the epidermis is required for MMP-28 induction [10] .
MMP-28 is also expressed in a variety of carcinomas [6] . In oral squamous cell carcinoma and oesophageal carcinoma cells, antisense knockdown of MMP-28 causes a reduction in anchorage-independent growth. In epithelial cells, evidence also suggests that MMP-28 can induce an EMT (epithelialmesenchymal transition) via activation of latent TGF-β (transforming growth factor β) [11] .
In primary keratinocytes, expression of MMP28 was induced by TNFα (tumour necrosis factor α) [11] . The proximal promoters of both human and mouse MMP28 genes have been isolated, and partially characterized in immortalized keratinocytes (HaCaT) [3] . The MMP28 promoter has no TATA box, nor AP-1 (activator protein 1) motif often found in the genes of inducible MMPs [12] . Conserved motifs were identified that could control the expression of MMP28 including a GT-box situated 300 bp upstream from the translation start site that binds both Sp1 (specificity protein 1) and Sp3 proteins, and is essential for the basal expression of MMP28 in HaCaT cells. The Sp family of transcription factors recognize and bind specifically to GC and GT DNA motifs [13] . Several isoforms of Sp1 and Sp3 have been described [14, 15] . These GC-and GT-boxes are required for the expression of numerous genes and are involved in processes, e.g. regulating cell growth, cell cycle and developmental patterning [16] .
Work in our laboratory and elsewhere has shown that HDAC (histone deacetylase) inhibitors are chondroprotective in a number of models [17] [18] [19] . The induced expression of many MMPs is decreased by HDAC inhibitors in chondrocytes, but, interestingly, the basal expression of a subset of genes is increased, and these include MMP28. MMP expression is regulated primarily at the level of transcription; however, little is known about the role of chromatin modification in this process [20] . Eukaryotic chromatin is formed from DNA wound around a histone octamer consisting of two molecules each of histones H2A, H2B, H3 and H4. Chromatin structure and function can be modified by post-translational modifications such as acetylation. Acetylation of positively charged lysine residues in the N-terminal tails of histones is mediated by HATs (histone actyltransferases). Simplistically, this is thought to regulate expression of a subset of genes by loosening the histone-DNA complex and allowing access of the transcriptional machinery. Conversely, histone deacetylation is catalysed by HDACs. HATs and HDACs are recruited to their target promoters through a physical interaction with sequence-specific transcription factors. In addition, HATs and HDACs can modify many other signalling proteins and transcription factors including both Sp1 and Sp3 [21] [22] [23] .
In the present study, we show that HDAC inhibitors induce the MMP28 promoter and that this effect is mediated through Sp1 at a promoter proximal GT-box. Sp factors are acetylated in response to HDAC inhibitors, bind to the conserved GT-box of the MMP28 promoter, potentially working in conjunction with HDAC1, p300, P/CAF [p300/CREB (cAMP-response-element-binding protein)-binding protein-associated factor] and STRAP (serine/threonine kinase receptor-associated protein).
EXPERIMENTAL

Plasmid constructs
The pGL3-344MMP28wt (wt, wild-type), pGL3-344MMP28mt (mt, mutant) and MMP28 promoter deletion constructs were as described previously [24] . The Sp1 and Sp3 cDNAs were a gift from Professor G. Suske (Institute of Molecular Biology and Tumour Research, Philipps-University of Marburg, Marburg, Germany), while Sp2 cDNA was purchased from MRC Geneservice. These were subcloned into a modified pcDNA4 vector to include a C-terminal FLAG tag to give pcDNA4flagSp1, pcDNA4flagSp2 and pcDNA4flagSp3. pCDNA3GAL4-p300, pRSV-CBP and pcDNA-PCAF were donated by Professor Tony Kouzarides (Department of Pathology, University of Cambridge, Cambridge, U.K.). The STRAP expression construct pcDNA3.1-STRAP was a gift from Dr Pran Datta (Vanderbilt University Medical Centre, Nashville, TN, U.S.A.).
Cell culture
HeLa cells were cultured in DMEM (Dulbecco's modified Eagle's medium; Invitrogen) supplemented with 10 % (v/v) FBS (fetal bovine serum; Sigma), 2 mM glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin. Serum-free conditions omitted the FBS. For assays, cells were grown to confluency and starved of serum for 24 h prior to treatment for 6 h with 10-500 ng/ml TSA (trichostatin A; Calbiochem), 0.5-8 mM VPA (valproic acid; Calbiochem), 0.5-10 mM NaB (sodium butyrate; Calbiochem), 100 nM okadaic acid (R&D Systems), 10 μM UO126 (R&D Systems), 20 μM SP610025 (R&D Systems) or 1 μM SB203580 (R&D Systems).
RNA isolation and cDNA synthesis
Cells were grown to confluency and RNA extracted using TRIzol ® reagent (Invitrogen). cDNA was synthesized from 1 μg of total RNA using Superscript II reverse transcriptase (Invitrogen) and random hexamers in a total volume of 20 μl, according to the manufacturer instructions. cDNA was stored at − 20
• C.
Quantitative RT (reverse transcription)-PCR
MMP primers and probes have been previously described and validated [7] . The 18S rRNA gene was used as an endogenous control to normalize for RNA loading (18S rRNA primers and probes were purchased from Applied Bioscience). Relative quantification of genes by the standard curve method was performed using the ABI Prism 7700 sequence detection system in accordance with the manufacturer's protocol. PCRs contained 5 ng of reverse transcribed RNA (1 ng for 18S), 50 % Taqman 2 × Master mix (Applied Biosystems), 100 nM each of primer and 200 nM probe in a total volume of 25 μl. Conditions for the PCR were 2 min at 50
• C and 10 min at 95 • C, followed by 40 cycles of 15 s at 95
• C and 1 min at 60
Reporter assays
HeLa cells were plated at 2 × 10 4 cells per well in a 24 well plate and grown overnight to approx. 80 % confluency. Cells were transiently transfected with FuGENE ® 6 (Roche) at a 3:1 ratio of FuGENE ® 6/DNA according to the manufacturer's instructions, and incubated for 24 h. Unless stated otherwise, promoter-reporter plasmids were used at 200 ng per well, with co-transfected expression plasmids (or empty vector equivalents) used at 100 ng per well (Figures 4 and 6 ), or 10 ng/well (Figure 9 ), following initial titration. Hence, within an experiment, the total amount of plasmid DNA transfected into each well was constant. The cells were washed in HBSS (Hanks balanced salt solution; Invitrogen) three times and incubated in serum-free medium for 24 h. When required, the cells were either treated with TSA (50 ng/ml) for 6 h or mock-treated with DMSO. Cells were washed with ice-cold PBS and lysed in 1 × passive lysis buffer (Roche) according to the manufacturer's instructions. Luciferase assays were performed following the manufacturer's instructions (Roche) and are presented as relative light units or the fold-change compared with the control.
Immunoprecipitation
HeLa cells (2 × 10 6 ) in 10 cm dishes were transiently transfected with 10 μg of pcDNA4Flag-Sp1 or pcDNA4Flag-Sp3 expression plasmids using FuGENE ® 6 (as above) and incubated for 24 h. Cells were washed with HBSS three times and incubated overnight with serum-free medium. Cells were treated with or without 50 ng/ml TSA for 6 h. Cells were washed with icecold PBS and harvested in 500 μl of RIPA buffer [50 mM Tris/HCl (pH 7.4), 1 % Nonidet P40, 0.25 % deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM NaF and one EDTA-free protease inhibitor tablet (Roche)], and incubated at 4
• C for 15 min with rotation. The protein concentration in the supernatant was measured and equalized. The supernatant was pre-cleared by adding 30 μl of 50% (v/v) slurry of Protein Aagarose beads/PBS for 15 min while rotating at 4
• C. Beads were pelleted at 12 000 g for 2 min. The supernatant was incubated with 4 μl of rabbit anti-Sp1 IgG or rabbit anti-Sp3 IgG (Santa Cruz Biotechnology, catalogue numbers sc-59x and sc-644x respectively) for 2 h at 4
• C with rotation. A 50 % slurry of Protein A-agarose beads/PBS was added and incubated at 4
• C for a further hour while rotating. The beads were washed three times in RIPA buffer and then resuspended in SDS sample buffer and heated to 100
• C for 5 min; proteins were then separated by SDS/PAGE (10 % gels). The proteins were transferred on to PVDF membrane, blocked with 5 % non-fat skimmed milk powder in PBS/0.1 % Tween 20 and probed with antibodies against pan-(acetyl lysine) residues (Cell Signaling Technologies, catalogue number #9441S). The membranes were stripped with Strong stripping buffer (Chemicon) and reprobed with anti-Sp1 or anti-Sp3 antibodies and visualized with chemiluminesence (Pierce).
EMSA (electrophoretic mobility-shift assay)
HeLa cells were grown to confluency in a 15 cm plate and washed with ice-cold PBS. Cells were pelleted at 500 g and resuspended in 1 ml of PBS containing 0.1 % Nonidet P40 for approx. 30 s. After centrifugation at 12 000 g for 10 s, the supernatant was removed and the nuclear pellet was resuspended in 3 vol. of high-salt buffer [25 mM Hepes (pH 7.9), 500 mM KCl, 0.5 mM MgSO 4 , 1 mM DTT (dithiothreitol) and 1 × EDTA-free protease inhibitors (Roche)] and incubated on ice for 20 min. The lysate was centrifuged for 2 min at 12 000 g and the supernatant was collected. The protein concentration was determined using Bradford reagent (Bio-Rad). Nuclear extracts were aliquoted and stored at − 80
• C. MMP28 oligonucleotides (MMP28 wt, 5 -GCGGGGTGG-GTGGGGCGGGAG-3 and MMP28 mt, 5 -GCGGGGTGGTTT-GGGCGGGAG-3 , mutated residues are indicated in bold) or Sp1 consensus oligonucleotides (5 -ATTCGATCGGGGCG-GGGCGAGC-3 ) were resuspended in annealing buffer [20 mM Tris/HCl (pH 7.4), 2 mM MgCl 2 and 50 mM NaCl] to a concentration of 100 μM. Oligonucleotides were heated to 95
• C for 5 min and left to cool to room temperature (22 • C). Annealed oligonucleotides were end-labelled with [γ -32 P]ATP (Amersham) using polynucleotide kinase (Promega) and unincorporated radioactivity was removed on a G25 spin column (GE Healthcare). Then, 1 μl of probe was incubated with 5 μg of nuclear extract, 1 μg of dI-dC, 1 μl of binding buffer [100 mM Tris/HCl (pH 7.5), 5 mM MgCl 2 , 5 mM DTT, 500 mM NaCl and 50 % glycerol], 1 μl of competitor in a 10 μl final volume with water. The binding reaction was incubated on ice for 30 min. For supershifts the nuclear extract was pre-incubated with 1 μl of antibody (anti-Sp1 antibody and anti-Sp3 antibodies were from Santa Cruz Biotechnology, catalogue numbers sc-59x and sc-644x respectively) on ice for 20 min prior to the addition of the remaining components of the binding reaction. Loading buffer (1 μl) without dye (30 % glycerol) was added and complexes separated on a 5 % acrylamide gel at 150 V. The gel was dried and visualized by autoradiography.
Oligonucleotide pulldown assay
MMP28 oligonucleotides (wt and mt, see above) were biotinylated at the 5 end of the top strand (Sigma Genosys). Oligonucleotides (0.1 μg/μl) were resuspended in annealing buffer [20 mM Tris/HCl (pH 7.4), 2 mM MgCl 2 and 50 mM NaCl], heated to 95
• C for 5 min and left to cool to room temperature. HeLa cells were grown to confluency in a 15 cm dish. Cells were washed in PBS and lysed in 500 μl of Schindler's buffer [50 mM Tris/HCl (pH 7.9), 0.1 mM EDTA, 10 % glycerol, 10 mM NaF, 150 mM NaCl, 1 % Nonidet P40, 1 mM DTT and 1 × EDTA-free protease inhibitors (Roche)] and incubated for 30 min at 4
• C with rotation. The lysate was centrifuged at 12 000 g for 5 min. The protein concentration in the supernatant quantified using Bradford reagent. The lysate was pre-cleared with 50 % (v/v) slurry of streptavidin-coated resin (Pierce) in Schindler's buffer for 15 min at 4
• C with rotation. The resin was removed by centrifugation at 12 000 g for 1 min. The supernatant was incubated with 1 μg of annealed oligonucleotide and 50 μl of 50% streptavidin-coated resin at 4
• C for 2 h with rotation. The beads were washed three times in Schindler's buffer. The protein was eluted in elution buffer [7 M urea, 4 % CHAPS, 2 M thiourea, 50 mM DTT and one protease inhibitor tablet (Roche)] and separated by SDS/PAGE. An approx. 37 kDa band was excised from the wt lane and analysed by tryptic digest and MS. STRAP was identified using Mascot software (http://www.matrixscience.com).
siRNA (small interfering RNA) knockdown
HeLa cells (2 × 10 4 ) were plated in each well of a 24 well plate and incubated overnight. The cells were tranfected with siRNA targeted to HDAC1 (Dharmafect SmartPool) using Dharmafect1 (Dharmacon) and incubated for 24 h at 37
• C. The medium was changed and the cells were further transfected with 0.2 μg of pGL3-344 MMP-28wt promoter construct using FuGENE ® 6 (Roche) and incubated for 24 h. The cells were washed with PBS and lysed in 1 × lysis buffer (Roche). Luciferase assays were performed following the manufacturer's instructions (Roche). In parallel, wells were harvested at the end of the experiment into TRIzol ® and RNA was purified. This was reverse-transcribed as above and 50 ng of cDNA used in RT-PCR for HDAC1 using the forward primer 5 -CAGCCTAGTGCGGTGGT-CTTACAGTG-3 and the reverse primer 5 -CTCCCAGCATC-AGCATAGGCAGGTTA-3 , at an annealing temperature of 58
Statistical analysis
Comparison between groups was by Student's t test. In order to combine data from replicate experiments, data are plotted as the fold-change compared with the control.
RESULTS
MMP28 expression is induced by HDAC inhibitors
Our previous studies have demonstrated that HDAC inhibitors have no effect on the basal expression of the majority of MMP genes, but our early data in SW1353 chondrosarcoma cells showed an induction in MMP17, MMP23 and MMP28 expression [19] . Figure 1 shows that, in HeLa cells, MMP28 expression is induced in a dose-dependent manner by 10-100 ng/ml TSA ( Figure 1A) , 0.5-10 mM NaB ( Figure 1B ) and 0.5-8 mM VPA ( Figure 1C) , with maximum induction seen at 50 ng/ml TSA, 5 mM NaB and 8 mM VPA. The dose-dependent induction of MMP28 expression by these different chemical classes of HDAC inhibitor demonstrates the specificity of the effect, since the non-specific activities of each class are unlikely to overlap. A similar pattern of induction was seen in HeLa, SW1353, C28/I2 and SV40-MRC5 cells, and further experiments were performed with the former cell line. Figure 2 (A) shows that expression from human MMP28 promoter-reporter constructs, transiently transfected into HeLa cells, is also induced by TSA. A deletion set from − 3031 to − 344 bp of the human MMP28 promoter showed strong (between ∼ 16-fold and ∼ 27-fold) induction of reporter gene expression. Deletion between − 344 and − 298 bp leads to a fall in TSA induction to ∼ 7-fold with the empty pGL3-basic vector retaining ∼ 2.5-fold induction.
The − 344/− 298 bp region contains a previously described GTbox, which contributes to basal expression of the gene in other cell types. Figure 2(B) shows that functional mutation of this site (pGL3-344MMP28mt) abrogates TSA induction of the − 344 bp MMP28 wt (pGL3-344MMP28wt) promoter construct. EMSA shows the same pattern of binding to the MMP28 GT-box and to a consensus Sp1-binding oligonucleotide ( Figure 3A , and results not shown). Of the specific protein complexes observed, supershift analysis identifies the slowest migrating complex as containing Sp1, whereas the two more rapidly migrating complexes contain Sp3 ( Figure 3B ). No evidence of Sp2 binding was observed. Recombinant Sp1 alone binds poorly to the oligonucleotide, but binding is greatly enhanced with the addition of nuclear extract suggesting synergy with other nuclear proteins.
TSA induces the MMP28 promoter via Sp1 at the GT-box
The pGL3-344MMP28wt or pGL3-344MMP28mt promoter constructs were co-transfected with pcDNA4FlagSp1, pcDNA4FlagSp2 or pcDNA4FlagSp3. Figure 4(A) shows that overexpression of Sp1 induces expression of the − 344 bp MMP28wt construct, and this is abrogated by the GT-box mutation. Sp3 overexpression does not induce expression from the − 344 MMP28wt promoter construct. Similarly, Sp2 has no effect (results not shown). Figure 4 (B) shows that treatment with TSA superinduces the Sp1-induced pGL3-344MMP28wt reporter expression, demonstrating that TSA mediates its induction of the pGL3-344MMP28wt construct via Sp1 at the GT-box.
TSA induces acetylation, but not expression, of both Sp1 and Sp3
Western blot analysis (either before or after immunoprecipitation) demonstrated that treatment of cells with TSA does not increase expression of Sp1 or Sp3 ( Figures 5A, 5C, 5D and 5F ). Previous studies suggests that both of these factors can be acetylated [23, [25] [26] [27] . In order to demonstrate this in the system used in the present study, cells were treated with or without TSA and whole-cell extracts were harvested. Extracts were immunoprecipitated with anti-Sp1 or anti-Sp3 antibodies, and these immunoprecipitates were subjected to Western blot analysis and probed first with an anti-pan (acetyl lysine) antibody, then stripped and reprobed with the precipitating antibody. Figures 5(B) and 5(E) show that both Sp1 and Sp3 are acetylated in response to TSA treatment, but, interestingly, only one isoform of each protein identified by Western blot analysis with each cognate antibody appears to be acetylated. The immunoprecipitation Western blot analysis do show additional bands not seen in the Western blots before immunoprecipitation. A band of approx. 50 kDa is a non-specific cross-reaction with the heavy chain of IgG, and other bands are probably due to an increase in sensitivity since the immunoprecipitation effectively concentrates the starting sample.
HATs mediate Sp1 induction of the MMP28 promoter
Since TSA mediates its induction of MMP28 via Sp1, and Sp1 is acetylated in response to TSA, a number of HATs were assessed as potential Sp1 acetyl transferases in this system. Expression constructs for p300, CBP [CREB (cAMP-responseelement-binding protein)-binding protein], P/CAF and equivalent mutants lacking the HAT domain were co-transfected with the pGL3-344MMP28wt construct with or without an Sp1 expression construct. Figure 6 (A) shows that basal expression from the pGL3-344MMP28wt promoter is induced by p300, but not by CBP or P/CAF, compared with the empty vector controls. This is largely dependent on an active HAT domain [compare the delta HAT MMP28 promoter constructs were cloned into pGL3 upstream of the luciferase reporter gene. HeLa cells were transiently transfected with these constructs overnight, washed and incubated in serum-free medium for a further 24 h, and then treated with or without TSA (50 ng/ml) for 6 h. Cells were harvested and the luciferase assay performed. (A) A deletion set from − 3031 to − 298 bp of the MMP28 promoter. (B) A 2 bp mutation was introduced into the GT-box contained within the pGL3-344MMP28wt construct to give pGL3-344MMP28mt. Results are presented as the fold relative light units in the presence of TSA compared with untreated, and are plotted as the means + − S.E.M. of three independent experiments each in triplicate (n = 9).
Figure 3 Sp1 and Sp3 bind to the MMP28 GT-box sequence
(A) EMSAs were performed using 32 P-labelled 37-mer MMP28 wt probe. Lane 1 shows the free probe. Nuclear extracts were prepared from HeLa cells and incubated with the labelled probe (lane 2). Recombinant Sp1 (rec Sp1) protein was incubated with the probe (lane 3) and in the presence of nuclear extract (lane 4). Unlabelled MMP28wt/MMP28 mt/Sp1 consensus oligonucleotide unlabelled competitor was added (lanes 5, 6 and 7). (B) A supershift assay was performed using antibodies against Sp1, Sp2 or Sp3.
(dHAT) construct with wt]. In the additional presence of Sp1, p300 and P/CAF (but again, not CBP) there was further induction of the pGL3-344MMP28wt promoter. Although Sp1 does induce the pGL3-344MMP28mt construct to some extent, p300 cannot further induce the expression, although P/CAF does, suggesting an additional site of action for this HAT ( Figure 6B ). 
siRNA-mediated knockdown of HDAC1 induces the MMP28 promoter
TSA inhibits all of the 11 classical HDACs to some extent [28] . HDAC1 has been implicated in Sp1-mediated repression of a number of genes [26, 29] . Cells were transfected with HDAC1 siRNA or a scrambled version and then, 24 h later, further transfected with the pGL3-344MMP2wt promoter construct. Figure 7 (A) demonstrates that knockdown of HDAC1 expression induces the MMP28 promoter. Figure 7 (B) shows that siRNA targeted to HDAC1 successfully knocks down expression of HDAC1 at the mRNA level.
Phosphorylation events have on impact upon TSA induction of the MMP28 promoter
Since Sp1 is known to undergo phosphorylation either increasing or decreasing its activity [30] , and in some signalling pathways phosphorylation and acetylation can be competing modifications, cells transfected with the pGL3-344MMP28wt promoter-reporter construct were treated with a protein phosphatase inhibitor, okadaic acid. This compound has previously been shown to HeLa cells were treated with or without 50 ng/ml TSA for 6 h. Cells were harvested and whole-cells extracts were prepared. Cell extracts were immunoprecipitated (IP) with antibodies (α) against Sp1 or Sp3 and Protein G-Sepharose beads. The beads were washed and proteins were eluted by heating in SDS sample buffer. Proteins were separated by SDS/PAGE (10 % gels) and transferred on to a PVDF membrane for Western blot analysis (WB). (A) Whole-cell extracts were probed using antibodies against Sp1. (B) Immunoprecitated proteins were probed using a pan-(acetyl lysine) antibody (αAc Lys). (C) The membrane was stripped and reprobed using antibodies against Sp1. (D) Whole-cell extracts probed using antibodies against Sp3. (E) Immunoprecitated proteins were probed using a pan-(acetyl lysine) antibody. (F) The membrane was stripped and reprobed using antibodies against Sp3. The molecular mass in kDa is indicated on the left-hand side of each.
increase the level of Sp1 phosphorylation [30] . Figure 8 (A) clearly shows that okadaic acid reduces the ability of TSA to induce the MMP28 promoter from approx. 8-fold to 2-fold.
Since the MEK [MAPK (mitogen-activated protein kinase)/ ERK (extracellular-signal-regulated kinase) kinase]/ERK pathway can lead to phosphorylation of Sp1, we repeated the above experiment treating cells with ERK, p38 MAPK or JNK (cJun N-terminal kinase) inhibitors prior to treatment with TSA. Interestingly, Figure 8(B) shows that the JNK inhibitor SP610025 decreases the induction of the MMP28 promoter by TSA. The impact of either pharmacological inhibitor could be direct or indirect, and the effect of the JNK inhibitor may suggest a role for c-Jun in MMP28 expression.
STRAP binds to the MMP28 promoter
In order to identify other proteins which might form complexes at the MMP28 promoter GT-box, we performed oligonucleotidepulldown assays with a 37-mer biotinylated oligonucleotide which spans the conserved GT-box. Protein complexes formed on the wt oligonucleotide were compared with those on a mt oligonucleotide with a 2 bp mutation in the GT-box. Pulldowns were performed and proteins were separated by SDS/PAGE and silver stained ( Figure 9A ). A 37 kDa protein was identified which bound the wt oligonucleotide, but not the mt oligonucleotide. This band was excised and identified by MS as STRAP. Of 31 peptides in the tryptic digests, nine were used by Mascot to identify STRAP with a probability-based Mowse score of 94 Figure 6 HATs mediate Sp1 induction of the MMP28 promoter (A) HeLa cells were co-transfected with pGL3-344MMP28wt construct and HAT expression constructs expressing pcDNAGAL4-p300/pRSV-CBP/pcDNA3-P/CAF or empty vectors. Constructs expressing mt co-activators with no HAT (dHAT) activity were also co-transfected. Following an overnight incubation, the cells were harvested and a luciferase assay was performed. (B) HeLa cells were co-transfected with pGL3-344 MMP28wt or pGL3-344 MMP28mt constructs and the co-activators, and incubated overnight. A luciferase assay was performed as above. Results are presented as relative light units plotted as means + − S.E.M. from a representative experiment in triplicate (n = 3).
(P = 0.0012). Sp1 was not identified as a differentially bound protein in this experiment, probably reflecting its abundance or its ability to bind to sites outside of the GT-box in the mt sequence.
STRAP increases the Sp1 induction of the MMP28 promoter
In order to test whether STRAP has any effect on the MMP28 promoter we co-transfected HeLa cells with the pGL3-344MMP28wt luciferase reporter, pcDNA4Flag-Sp1 and pcDNA3.1-STRAP. STRAP alone had no effect on the promoter above background. However, when STRAP was co-transfected with Sp1, STRAP was able to increase the Sp1 induction of the MMP28 promoter ( Figure 9B) .
DISCUSSION
The present study shows that the expression of MMP28 is regulated by acetylation. Previous studies have identified conserved motifs that could control the expression of MMP28 including a GT-box situated 310 bp upstream from the translation start site that binds both Sp1 and Sp3 proteins, and is essential for MMP28 basal expression in keratinocytes [24] . We have shown that broad spectrum HDAC inhibitors, such as TSA and NaB, can induce MMP28 expression in a number of cell types and that this effect is predominantly mediated through the conserved GTbox with functional mutation abrogating induction of the MMP28 promoter by TSA. EMSAs and supershift assays have shown that Sp1 and Sp3 factors can bind to the MMP28 promoter GT-box sequence. However, transient transfection assays with the wt and mt promoters show that Sp1, but not Sp3, can induce the MMP28 promoter via this site. Some minimal transactivation of the pGL3-344MMP28mt construct by Sp1 suggests that sequences outside the GT-box within − 344 can mediate this effect and other GCrich sequences can be identified. Sp1 and Sp3 both bind GT/GCrich sequences, these interactions can be co-operative or Sp3 can decrease Sp1-dependent transactivation with the ratio of each protein being a determining factor. When these factors were added together, no synergy or competition was observed at the MMP28 promoter (results not shown). This could be due, however, to the delicate balance of each factor required. Studies have shown that the DNA-binding affinity of Sp factors and their ability to transactivate are influenced at the post-translational level by both phosphorylation and acetylation [16, 23, 27, 31, 32] . Western blot analysis and immunopreciptitaion experiments showed that TSA does not affect the expression of Sp1 and Sp3, but does induce their acetylation. Acetylation of Sp3 in its inhibitory domain can turn it from a transcriptional repressor to an activator [22] . This does not occur on the MMP28 gene since, even in the presence of TSA, Sp3 still does not transactivate the MMP28 promoter (results not shown). Studies have shown that Sp1 can be acetylated at Lys 703 [23, 26, 27] . This acetylation can alter protein-protein interactions and modify the Sp1-containing protein complexes which act at GC/GT-boxes.
The phosphatase inhibitor okadaic acid, previously shown to increase phosphorylation of Sp1 [30] , abrogates both basal expression of the MMP28 promoter and its induction by TSA. Phosphorylation of Sp1 has been shown to increase or decrease its transactivation ability dependent on the phosphorylation site and biological context [30] . The specific JNK inhibitor is the only MAPK inhibitor to have on impact upon TSA induction of the MMP28 promoter. Since it reduces the TSA induction of the MMP28 promoter (rather than enhancing it, which would be expected if JNK were the Sp1 kinase), this is not likely to be via phosphorylation of Sp1.
Transcriptional co-activators such as p300/CBP and P/CAF are recruited to sequence-specific transcription factors and have intrinsic HAT activity. Recruitment of P/CAF and p300 has previously been shown to be correlated with acetylation of Sp1 after treatment with TSA [23] . We showed that both P/CAF and p300 were able to induce the MMP28 promoter in the presence of Sp1 and, at least for p300, this is HAT-dependent.
Since it had previously been shown that Sp1 could recruit HDAC1 [26, 33] , we investigated the function of this HDAC on the MMP28 gene. Knockdown of HDAC1 with siRNA induced the MMP28 promoter in the same manner as treatment with TSA, suggesting that inhibition of HDAC1 is in part responsible for the action of broad spectrum HDAC inhibitors on MMP28 expression. Sp1 has previously been reported to regulate the 12(S)-lipoxygenase gene by recruiting both c-Jun and HDAC1 [26, 34] . A role for c-Jun in the Sp1-site-dependent regulation of MMP28 expression is also consistent with the ability of the JNK inhibitor SP610025 to abrogate TSA induction of the MMP28 promoter.
Recombinant Sp1 alone does not bind strongly to the MMP28 promoter GT-box, but binding is enhanced in the additional presence of nuclear extracts. As discussed above, this again suggests that Sp1 binds and acts in complex with other protein factors. Oligonucleotide pulldown assays were performed to identify novel proteins that bind to the MMP28 promoter GTbox. We identified a 37 kDa protein that bound to the wt GT-box sequence, but not to the non-functional mt. This was identified as STRAP. STRAP is a TGF-β receptor-interacting protein which associates with both type I and type II TGF-β receptors and is involved in TGF-β signalling [35, 36] . STRAP synergizes with Smad7 and inhibits TGF-β-induced transcriptional responses. The expression of STRAP is also increased in a number of human cancers [37] and it can act via TGF-β-independent mechanisms, e.g. via the ERK pathway [38] . STRAP can localize to both cytoplasm and nucleus and has been shown to inhibit the Figure 9 STRAP binds to the MMP28 promoter (A) Whole-cell extracts were prepared from HeLa cells. The extracts were incubated with a biotinylated MMP28wt or mt 37-mer oligonucleotide containing the GT-box and streptavidin-coated beads. The beads were washed, and eluted proteins were separated by SDS/PAGE (10 % gel). The gel was silver stained. A 37 kDa band that was pulled down with the wt oligonucleotide, but was absent in the mt pulldown, was excised from the gel and analysed using MS. The molecular mass in kDa is indicated on the left-hand side. (B) HeLa cells were co-transfected with pGL3-344MMP28wt and a construct expressing STRAP (pcDNA3-STRAP) and Sp1 (pcDNA4Flag-Sp1). The cells were incubated overnight and a luciferase assay was performed. Results are presented as relative light units plotted as means + − S.E.M. from a representative experiment in triplicate (n = 3).
co-activator function of the EWS (Ewing sarcoma) protein by displacing p300 from the activation complex [39] . We have shown that transfected STRAP had little or no effect alone at the MMP28 promoter, but was able to increase Sp1-mediated activation further when co-transfected. In summary, we present evidence that the expression of MMP28 is regulated by acetylation. The MMP28 gene is induced by HDAC inhibitors in a number of cell lines. This is dependent on a promoter proximal GT-box which binds a protein complex containing Sp1. A number of proteins are involved in transactivation of the gene including p300, P/CAF, HDAC1, STRAP and potentially c-Jun. A number of HDAC inhibitors are being developed as cancer chemotherapeutics and it has been mooted that the ability of such compounds to repress expression of some MMPs may enhance their efficacy [40, 41] .
The present study underlines the need to examine the effects of such compounds across the MMP family, since MMP-28 is induced by HDAC inhibitors and may also promote tumorigenesis and/or metastasis.
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